1. Home
  2. Browse
  3. HRA010624
HRA010624
   HRA010624.xlsx
Title:
Evaluating the Clinical Utility of Next-Generation Sequencing Liquid Biopsy in Advanced NSCLC Patients: Insights from a Chinese Cohort
Release date:
2025-04-16
Description:
In this study, we explored the potential of cell-free circulating tumor DNA (ctDNA)-based next-generation sequencing (NGS) as a tool for personalizing treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Despite the growing interest in ctDNA as a non-invasive alternative to tissue biopsy for mutational profiling, its clinical application remains underexplored in Chinese NSCLC populations. Through a retrospective analysis of NGS results from 522 Chinese patients diagnosed with stage III or IV NSCLC, we assessed the feasibility of using ctDNA-based NGS to detect mutations and guide targeted therapies.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA036895
Study type:
Cohort Study
Disease name:
lung cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC005567
DAC name:
ctDNA Data Mgmt. Committee
Contact person:
shan guangyu
Email:
guangyushan@usci-ivd.cn
Description:
The ctDNA Data Management Committee was established for the management of targeted sequencing data of patients with advanced lung cancer.
Individuals & samples
Files
Request Data
Submitter:   shan guangyu / guangyushan@usci-ivd.cn
Organization:   Beijing USCI Medical Devices Co., Ltd.
Submission date:   2025-03-04
Requests:   -